Bio

Yang Chu has deep experience representing leading issuers and investment banks in capital market transactions, with a particular focus on IPOs and secondary listings, including headline-making first HKEX deals for pre-revenue biotech companies, dual-class share structures and secondary listings. After the IPO, Yang is a trusted adviser to HKEX-listed companies on complex disclosure, compliance and corporate governance issues. His experience in debt capital markets covers the spectrum, from high-yield and credit-enhanced bond offerings and private placements to multi-billion-dollar debt programmes for China’s leading corporates. Yang also advises leading Chinese corporates and global PE funds on cross-border investments and acquisitions, including Hong Kong public takeovers. He is the co-author of the Hong Kong chapter of Getting the Deal Through: Private M&A.